Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLIN versus QUIBRON T SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLIN versus QUIBRON T SR.
AMINOPHYLLIN vs QUIBRON-T/SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective phosphodiesterase inhibitor, increasing intracellular cAMP and cGMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/mL). Maximum 800 mg/day.
None Documented
None Documented
Clinical Note
moderateAminophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Trovafloxacin
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Terminal t1/2: 3-12 hours (adults); 1-9 hours (children); prolonged in cirrhosis (up to 30 hours), heart failure, elderly. Clinical context: Narrow therapeutic index (5-15 mcg/mL); dosing interval adjusted based on t1/2.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4): 90% to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid). Biliary/fecal: minimal (<5%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Aminophylline."